Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:8691 |
Name | mycosis fungoides |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | DOID:8737 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma peripheral T-cell lymphoma cutaneous T cell lymphoma mycosis fungoides |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Mogamulizumab | mycosis fungoides | not applicable | detail... |
Unknown unknown | Lacutamab | mycosis fungoides | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01976585 | Phase Ib/II | CDX-301 + Poly ICLC | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Recruiting | USA | 0 |
NCT02232516 | Phase II | Lenalidomide + Romidepsin | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | Recruiting | USA | 0 |
NCT02542124 | Phase II | Interleukin-12 | NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | Unknown status | USA | 0 |
NCT02580552 | Phase I | MRG-106 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | Completed | USA | 0 |
NCT02616965 | Phase I | Brentuximab vedotin + Romidepsin | A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma | Recruiting | USA | 0 |
NCT02890368 | Phase I | TTI-621 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | Terminated | USA | 0 |
NCT02978625 | Phase II | Nivolumab + Talimogene laherparepvec | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Recruiting | USA | 0 |
NCT03011814 | Phase Ib/II | Durvalumab Durvalumab + Lenalidomide | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | Recruiting | USA | 0 |
NCT03063632 | Phase II | Interferon gamma + Pembrolizumab | Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome | Active, not recruiting | USA | 0 |
NCT03075553 | Phase II | Nivolumab | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Terminated | USA | 0 |
NCT03081910 | Phase I | CD5 CAR T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT03598998 | Phase Ib/II | Pembrolizumab + Pralatrexate | Pembrolizumab and Pralatrexate in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphomas | Recruiting | USA | 0 |
NCT03602157 | Phase I | ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | Recruiting | USA | 0 |
NCT03695471 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | Recruiting | USA | 0 |
NCT03713320 | Phase II | Vorinostat MRG-106 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides (SOLAR) | Terminated | USA | CAN | 6 |
NCT03837457 | Phase II | MRG-106 | PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study (PRISM) | Terminated | USA | 2 |
NCT03902184 | Phase II | Gemcitabine + Lacutamab + Oxaliplatin Lacutamab | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) | Recruiting | USA | 5 |
NCT03905135 | Phase I | Avelumab + rhIL-15 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | Recruiting | USA | 0 |
NCT04074746 | Phase I | Cyclophosphamide + Fludarabine AFM13 | Bispecific Antibody AFM13 Combined With NK Cells for Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Recruiting | USA | 0 |
NCT04101331 | Phase II | AFM13 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT) | Recruiting | USA | 9 |
NCT04185220 | Phase I | Mogamulizumab + rhIL-15 | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome | Active, not recruiting | USA | 0 |
NCT04217317 | Phase II | Bendamustine + CPI-613 | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04234048 | Phase I | Fenretinide | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
NCT04256018 | Phase II | Mogamulizumab | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sezary Syndrome | Recruiting | USA | 0 |
NCT04676087 | Phase Ib/II | Mogamulizumab | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | Not yet recruiting | USA | 0 |
NCT04747236 | Phase II | Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin | A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) | Not yet recruiting | USA | 0 |